Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
419 studies found for:    Open Studies | "Myelodysplastic Syndromes"
Show Display Options
Rank Status Study
21 Unknown  Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Conditions: Hemochromatosis;   Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Other: Venesection
22 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
23 Recruiting Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Lenalidomide;   Other: Placebo
24 Recruiting CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.
Conditions: Myelodysplastic Syndromes;   Acute Leukemia
Intervention: Drug: CIK-Cells
25 Recruiting Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
Conditions: Adult;   Myelodysplastic Syndromes
Interventions: Other: questionnaire administration;   Other: fatigue assessment and management;   Other: observation;   Other: quality-of-life assessment
26 Recruiting Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
Conditions: Myelodysplastic Syndromes;   Juvenile Myelomonocytic Leukemia
Intervention:
27 Recruiting Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Cladribine;   Procedure: Stem Cell Transplant;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cyclophosphamide
28 Recruiting A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: Luspatercept;   Other: Placebo
29 Not yet recruiting Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Intervention: Drug: CPI-613
30 Recruiting Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Imetelstat;   Drug: Placebo
31 Unknown  T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes
Intervention: Procedure: CD8+ T-cell depleted donor lymphocyte infusion
32 Recruiting PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.
Condition: Myelodysplastic Syndromes
Interventions: Other: research of disease-related factors;   Other: research of comorbidities;   Other: physical performance
33 Recruiting Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Conditions: Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Juvenile
Intervention: Drug: Azacitidine
34 Recruiting Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Conditions: Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: H3B-8800
35 Recruiting An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)
Conditions: Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Interventions: Drug: Azacitidine;   Drug: Durvalumab
36 Recruiting Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Interventions: Drug: Sertraline;   Procedure: Bone Marrow Aspirate/Biopsy
37 Recruiting Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Conditions: Acute Myeloid Leukemia (AML);   High-risk Myelodysplastic Syndrome (MDS)
Interventions: Drug: Volasertib;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Mitoxantrone
38 Recruiting Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
Interventions: Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Biological: WT1-Sensitized Allogeneic T-Lymphocytes
39 Recruiting Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
Conditions: Acute Myeloid Leukemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selinexor
40 Recruiting The National Myelodysplastic Syndromes (MDS) Study
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: Therapeutic

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years